Quick Answer
Elicio Therapeutics, Inc. reported Long-Term Debt of $9.41 million for fiscal year 2025.
Elicio Therapeutics, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $9.41M | -53.0% |
| 2024 | $20.03M | — |
| 2021 | $0.00 | -100.0% |
| 2020 | $635.0K | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.72M | — | +4.1% |
| June 30, 2025 | $9.34M | — | -53.4% |
| December 31, 2024 | $20.03M | — | — |
| September 30, 2021 | $0.00 | — | — |
| June 30, 2021 | $0.00 | — | — |
| March 31, 2021 | $0.00 | — | -100.0% |
| December 31, 2020 | $635.0K | — | — |
- Elicio Therapeutics, Inc. showed a decrease of -53.0% in Long-Term Debt compared to the prior fiscal year.
- Over the 2020–2025 period, Elicio Therapeutics, Inc.’s long-term debt has grown by 1381.4% (from $635.0 thousand to $9.41 million).
- The most recent figure is from Elicio Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: